سعر لاستيت 50 مجم 20 كبسولة 2022

Lastet etoposide 50 mg oral capsules, pack of 20 (Nippon Kayaku, Japan; Multipharma, Egypt); topoisomerase II inhibitor antineoplastic. The source row is marked "(n/a)" (not available).

• Small cell lung cancer, first-line in combination therapy.Population: AdultsDailyMed (U.S. National Library of Medicine)

• Myelosuppression (leucopenia, thrombocytopenia; nadirs at about 7-16 days), nausea and vomiting, alopecia, anorexia, mucositis, hypersensitivity reactions, and secondary acute leukaemia have been reported.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Previous hypersensitivity to etoposide or any component of the formulation.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Boxed warning: to be given under the supervision of a physician experienced in cancer chemotherapy; severe myelosuppression with resulting infection or bleeding may occur.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Dose-limiting bone marrow suppression (deaths reported): check platelet count, haemoglobin, white cell and differential counts before each cycle; withhold if platelets <50,000/mm3 or neutrophils <500/mm3; anaphylactic-like reactions (chills, fever, tachycardia, bronchospasm, dyspnoea, hypotension) may occur.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Can cause fetal harm when given to a pregnant woman (teratogenic in mice and rats); women of childbearing potential should avoid pregnancy.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Not known whether excreted in human milk; because of potential serious adverse reactions in nursing infants, decide whether to discontinue nursing or the drug.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Etoposide: Inhibits topoisomerase II, stabilising DNA cleavage and causing strand breaks; arrests cells in late S/G2 phase.